Oppenheimer Maintains Outperform on Viridian Therapeutics, Raises Price Target to $36
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell has maintained an Outperform rating on Viridian Therapeutics (NASDAQ:VRDN) and increased the price target from $35 to $36.
December 19, 2023 | 1:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Leland Gershell maintains an Outperform rating on Viridian Therapeutics and raises the price target from $35 to $36.
The increase in price target by a reputable analyst typically signals confidence in the company's future performance and can lead to positive investor sentiment in the short term. As the price target is only slightly raised, the impact may be moderate but still positive.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100